COO Cooper Companies (The)
Oligopoly contact lens franchise priced for stagnation; margin normalization alone covers today's price.
The story
Cooper is a two-segment medtech: CooperVision is the #3 global soft contact lens maker in a rational four-player oligopoly with recurring, consumer-driven demand (daily silicone hydrogels, myopia control via MiSight), and CooperSurgical is a fertility and women's health business built through acquisitions. It is a mature, mid-single-digit grower. GAAP margins are held down by heavy acquisition amortization and restructuring, and its acquired goodwill makes the reported capital base look bloated. The stock has de-rated on slowing lens growth, a weak fertility segment and activist pressure, so the question is whether margins can be normalized, not whether the franchise survives.
Growth of about 5% tracks the contact lens market plus share gains in dailies and myopia control, below the 7.3% historical CAGR, which was helped by acquisitions. I set the target margin at 21%, between GAAP (13-18%) and adjusted (~25%), because amortization and recurring restructuring are partly real costs; cost programs and portfolio pruning support a 5-year glide path. Sales-to-capital of 1.2 is a marginal organic figure: the reported 0.39 is distorted by acquisition goodwill and would wrongly penalize organic growth. That lens is why the baseline value of $0.83 is not credible.
Value drivers
| Revenue growth (Y1) | 5.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 8y |
| Target operating margin | 21.0% |
| Years to target margin | 5 |
| Sales-to-capital | 1.20 |
| Beta | 0.90 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 8.5% |
| Terminal WACC | 8.9% |
Valuation bridge
| PV of explicit FCFF | 2.62B |
| PV of terminal value | 4.83B |
| Equity value | 4.96B |
| ÷ shares → per share | $26.06 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 4.45B | 5.0% | 14.6% | 430.29M | 176.54M | 253.75M | 233.76M |
| 2 | 4.66B | 4.7% | 16.2% | 499.78M | 174.77M | 325.01M | 275.83M |
| 3 | 4.86B | 4.4% | 17.8% | 573.30M | 171.92M | 401.38M | 313.83M |
| 4 | 5.07B | 4.1% | 19.4% | 650.57M | 167.95M | 482.62M | 347.63M |
| 5 | 5.26B | 3.9% | 21.0% | 731.25M | 162.85M | 568.40M | 377.17M |
| 6 | 5.45B | 3.6% | 21.0% | 757.36M | 156.60M | 600.76M | 367.25M |
| 7 | 5.63B | 3.3% | 21.0% | 782.25M | 149.22M | 633.03M | 356.50M |
| 8 | 5.80B | 3.0% | 21.0% | 805.71M | 140.72M | 665.00M | 345.01M |
Key risks
- Contact lens share loss or price pressure from J&J, Alcon and Bausch in dailies and toric lenses
- Fertility and IVF demand stays cyclical and soft, and CooperSurgical gets sold at a discount
- Leverage (about $2.4B net debt) plus serial M&A destroying value instead of improving margins
Catalysts
- Activist-driven portfolio action (separating or selling CooperSurgical) or a margin-focused restructuring
- MiSight myopia control adoption and new daily silicone hydrogel launches lifting organic lens growth back above 6%